There is need of development of novel blood‐based biomarkers specifically for synucleinopathies and TDP‐43, 3R tauopathies, and 4R tauopathies, to enhance the clinical performance of a neurocognitive blood test for FTD and DLB. This evidence concerns the gene TARDBP and frontotemporal dementia.